# Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

> **NCT05022797** · PHASE2 · TERMINATED · sponsor: **Fundacion CRIS de Investigación para Vencer el Cáncer** · enrollment: 3 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma
- Drug Toxicity

## Interventions

- **DRUG:** Glucarpidase 1000 UNT [Voraxaze]

## Key facts

- **NCT ID:** NCT05022797
- **Lead sponsor:** Fundacion CRIS de Investigación para Vencer el Cáncer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-19
- **Primary completion:** 2022-11-22
- **Final completion:** 2022-11-22
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** closed because of low recruitment
- **Last updated:** 2024-05-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05022797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05022797, "Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05022797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*